Abstract: The present invention relates to a cosmetic composition comprising: from 30% to 89% by weight of at least one polar oil with respect to the total weight of the composition; from 6% to 45% by weight of at least one C2-C6 aliphatic monoalcohol with respect to the total weight of the composition; from 4% to 30% by weight of hexylene glycol with respect to the total weight of the composition; from 8% to 40% by weight of dipropylene glycol with respect to the total weight of the composition; and at least one hydrophilic active agent, said composition containing less than 15% by weight of water with respect to the total weight of the composition.

Abstract: The present application relates to a cosmetic composition comprising at least one ester corresponding to formula (I) below: R1COOR2??(I) in which R1 represents H or a linear or branched hydrocarbon-based radical, and R2 represents a linear or branched hydrocarbon-based radical, with the proviso that: when R2 is a linear hydrocarbon-based radical and R1 is H or a linear hydrocarbon-based radical, then 7?R1+R2?8; and when at least one of R1 and R2 is a branched hydrocarbon-based radical, then 8?R1+R2?10, with the proviso that, when R1 is tert-butyl, then R2 is not isohexyl. This composition can be used as a product for caring for and/or making up keratin materials, in particular the skin, the lips and/or the integuments.

Abstract: The present application relates to a cosmetic composition comprising, in a physiologically acceptable medium, at least one aprotic hydrocarbon-based volatile solvent comprising no more than one branch, the volatility of said solvent being such that the amount evaporated in 30 minutes is between 4.1 mg/cm2 and 24 mg/cm2. This composition can be used as a product for caring for and/or making up keratin materials, in particular the skin, the lips and/or the integuments.

Abstract: The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an asthma/allergy medicament for the treatment or prevention of asthma and allergy in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs.

Abstract: Keratin fibre makeup kit containing at least: a first composition with a surface energy of less than or equal to 30 mN/m, and a second composition with a surface energy such that the difference between its surface energy and that of the first composition is greater than or equal to 5 mN/m, and a viscosity of between 0.001 and 2 Pa·s.

Abstract: The present application relates to a cosmetic composition comprising at least one carbonic acid ester corresponding to formula (I) below: R1—O—CO—O—R2 ??(I) in which R1 and R2 are identical or different and represent a linear or branched hydrocarbon-based radical, with the proviso that: when R1 and R2 are linear, they each contain from 1 to 6 carbon atoms, with 6?R1+R2?7; and when R1 and/or R2 are branched, they each contain from 1 to 8 carbon atoms, with 6?R1+R2?9. This composition can be used as a product for caring for and/or making up keratin materials, in particular the skin, the lips and/or the integuments.

Abstract: The present application relates to a cosmetic composition comprising at least one ester corresponding to formula (I) below: R1COOR2 ??(I) in which R1 represents H or a linear or branched hydrocarbon-based radical, and R2 represents a linear or branched hydrocarbon-based radical, with the proviso that: when R2 is a linear hydrocarbon-based radical and R1 is H or a linear hydrocarbon-based radical, then 7?R1+R2?8; and when at least one of R1 and R2 is a branched hydrocarbon-based radical, then 8?R1+R2?10, with the proviso that, when R1 is tert-butyl, then R2 is not isohexyl. This composition can be used as a product for caring for and/or making up keratin materials, in particular the skin, the lips and/or the integuments.

Abstract: The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an asthma/allergy medicament for the treatment or prevention of asthma and allergy in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs.

Abstract: The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an asthma/allergy medicament for the treatment or prevention of asthma and allergy in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs.

Abstract: The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an asthma/allergy medicament for the treatment or prevention of asthma and allergy in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs.

Abstract: The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an asthma/allergy medicament for the treatment or prevention of asthma and allergy in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs.

Abstract: The present invention relates to combined preparation containing as active substance the following individual components, in the form of a kit-of-parts: monocyte derived cells, particularly cytotoxic macrophages, chemotherapy or immunotherapy drugs, for the simultaneous, separate or sequential use, for the treatment of cancer or infectious diseases.

Abstract: The present invention relates to combined preparation containing as active substance the following individual components, in the form of a kit-of-parts:

Abstract: The present invention relates to combined preparation containing as active substance the following individual components, in the form of a kit-of-parts: monocyte derived cells, particularly cytotoxic macrophages, chemotherapy or immunotherapy drugs, for the simultaneous, separate or sequential use, for the treatment of cancer or infectious diseases.

Abstract: The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an asthma/allergy medicament for the treatment or prevention of asthma and allergy in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs.

Abstract: The invention relates to monocyte derived cells, in a purified form and substantially free of contaminants, presenting antigenic epitopes on their membranes after interiorization and processing of at least an antigen-antibody complex formed between an antigen and an antibody, under appropriate conditions, said epitopes corresponding to proteolytic degradation products of said antigen,

Abstract: A transfer-resistant make-up or care composition, comprising: a fatty phase, and a volatile solvent comprising a linear decamethyltetrasiloxane and at least one additional solvent which has an evaporation speed that is greater than the evaporation speed of the linear decamethyltetrasiloxane.

Abstract: Filter devices for simultaneously removing leukocytes and viral inactivating agents from whole blood or blood fractions are disclosed. One type of device comprises (1) a housing surrounding (2) activated carbon and (3) a mechanically stable polymeric material which may optionally be modified to attach a ligand for leukocytes. General methods for removing leukocytes and viral inactivating agents from blood and plasma are also disclosed.

Abstract: Filter devices for simultaneously removing leukocytes and viral inactivating agents from whole blood or blood fractions are disclosed. One type of device comprises (1) a housing surrounding (2) activated carbon and (3) a mechanically stable polymeric material which may optionally be modified to attach a ligand for leukocytes. General methods for removing leukocytes and viral inactivating agents from blood and plasma are also disclosed.

Abstract: Filter devices for simultaneously removing leukocytes and viral inactivating agents from whole blood or blood fractions are disclosed. One type of device comprises (1) a housing surrounding (2) activated carbon and (3) a mechanically stable polymeric material which may optionally be modified to attach a ligand for leukocytes. General methods for removing leukocytes and viral inactivating agents from blood and plasma are also disclosed.